|
Sofia Kiriakidi, PhD
Postdoctoral Associate Biomedical Research Foundation, Academy of Athens Center for Translational Research, Biomedical Research Foundation e-mail: skyriakidi [at] bioacademy.gr |
Brief Bio
Sofia Kiriakidi graduated from the Department of Chemistry, University of Athens and pursued a Masters Degree in Theoretical Chemistry in Uppsala University, Sweden. She obtained her PhD from the Department of Chemistry of the University of Athens in 2021 and her doctoral thesis focused on the applications of theoretical and biophysical studies on rational drug design. Her doctoral studies were conducted at Prof. Thomas Mavromoustakos lab, in the Department of Chemistry of the University of Athens and at Dr Cournia’s lab, in the Biomedical Research Foundation of the Academy of Athens. During her doctoral studies, she has been working on the use of Quantum Mechanics for the study of chemical phenomena and reaction mechanisms investigation, as well as with Molecular Dynamics for the investigation of drug binding pathways and the study of biophysical properties of membranes and transmembrane proteins. She has been awarded a State Scholarship for her doctoral thesis by the Hellenic Foundation for Research and Innovation (HFRI) and the General Secretariat for Research and Technology (GSRT), under the HFRI PhD Fellowship grant (GA. no. 14551). She is currently working as a post-doctoral researcher in the Cournia Lab, where she employees molecular dynamics for the investigation of protein-protein interaction interfaces, as a possible drug strategy against oncogenic mutants.
Sofia Kiriakidi graduated from the Department of Chemistry, University of Athens and pursued a Masters Degree in Theoretical Chemistry in Uppsala University, Sweden. She obtained her PhD from the Department of Chemistry of the University of Athens in 2021 and her doctoral thesis focused on the applications of theoretical and biophysical studies on rational drug design. Her doctoral studies were conducted at Prof. Thomas Mavromoustakos lab, in the Department of Chemistry of the University of Athens and at Dr Cournia’s lab, in the Biomedical Research Foundation of the Academy of Athens. During her doctoral studies, she has been working on the use of Quantum Mechanics for the study of chemical phenomena and reaction mechanisms investigation, as well as with Molecular Dynamics for the investigation of drug binding pathways and the study of biophysical properties of membranes and transmembrane proteins. She has been awarded a State Scholarship for her doctoral thesis by the Hellenic Foundation for Research and Innovation (HFRI) and the General Secretariat for Research and Technology (GSRT), under the HFRI PhD Fellowship grant (GA. no. 14551). She is currently working as a post-doctoral researcher in the Cournia Lab, where she employees molecular dynamics for the investigation of protein-protein interaction interfaces, as a possible drug strategy against oncogenic mutants.
List of Publications:
1. Study of Candesartan Cilexetil: 2-Hydroxypropyl-β-Cyclodextrin Interactions: A Computational Approach Using Steered Molecular Dynamics Simulations S. Kiriakidi, Thomas Mavromoustakos, Supramolecules in Drug Discovery and Drug Delivery. Methods in Molecular Biology, vol. 2207, pp. 4570, ed: Springer, New York 2021, https://doi.org/10.1007/978-1-0716-0920-0_5
2. 2D DOSY NMR: A Valuable Tool to Confirm the Complexation in Drug Delivery Systems C. M.Chatzigiannis, S. Kiriakidi, Andreas G Tzakos, Thomas Mavromoustakos, Supramolecules in Drug Discovery and Drug Delivery. Methods in Molecular Biology, vol. 2207, pp. 235-246, ed: Springer, New York 2021, https://doi.org/10.1007/978-1-0716-0920-0_18
3. Interplay of cholesterol, membrane bilayers and the AT1R: A cholesterol consensus motif on AT1R is revealed S. Kiriakidi, C. Chatzigiannis, C. Papaemmanouil, A.G. Tzakos, Z. Cournia, T.Mavromoustakos, Computational and Structural Biotechnology Journal, vol.19, pp.110-120, 2020, https://doi.org/10.1016/j.csbj.2020.11.042
4. Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid A.D. Tsiailanis, A. Renziehausen, S. Kiriakidi, E.I. Vrettos, G. S. Markopoulos, N. Sayyad, B. Hirmiz, M.-I. Aguilar, M. P. Del Borgo, E. Kolettas, R. E. Widdop, T. Mavromoustakos, T. Crook, N. Syed, A. G. Tzakos, Free Radical Biology and Medicine, vol. 160, pp. 391-402, 2020, https://doi.org/10.1016/j.freeradbiomed.2020.08.007
5. A Journey to the Conformational Analysis of T-Cell Epitope Peptides Involved in Multiple Sclerosis. C. Koukoulitsa, E. Chontzopoulou, S. Kiriakidi, A. G. Tzakos, T. Mavromoustakos, Brain Sciences, vol. 10, pp. 356, 2020, https://doi.org/10.3390/brainsci10060356
6. Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor S.Kiriakidi, C. Chatzigiannis, C. Papaemmanouil, A. G. Tzakos, T. Mavromoustakos, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol. 1862, p. 183142, 2020 https://doi.org/10.1016/j.bbamem.2019.183142
7. Effects of Cholesterol on GPCR Function: Insights from Computational and Experimental Studies.S. Kiriakidi, A. Kolocouris, G. Liapakis, S. Ikram, S. Durdagi, T. Mavromoustakos in Direct Mechanisms in Cholesterol Modulation of Protein Function. Advances in Experimental Medicine and Biology, vol 1135, B. A. e. Rosenhouse-Dantsker A., Ed., ed: Springer, Cham, 2019, https://doi.org/10.1007/978-3-030-14265-0_5
8. Host-guest interactions between candesartan and its prodrug candesartan cilexetil in complex with 2-hydroxypropyl-β-cyclodextrin: on the biological potency for Angiotensin II antagonism D. Ntountaniotis, I. Andreadelis, T. F. Kellici, V. Karageorgos, G. Leonis, E. Christodoulou, S. Kiriakidi, J. Becker-Baldus, E. K. Stylos, M. V. Chatziathanasiadou, C. M. Chatzigiannis, D. E. Damalas, B. Aksoydan, U. Javornik, G. Valsami, C. Glaubitz, S. Durdagi, N. S. Thomaidis, A. Kolocouris, J. Plavec, A. G. Tzakos, G. Liapakis, T. Mavromoustakos, Molecular Pharmaceutics, vol. 16, pp. 1255-1271, 2019, https://doi.org/10.1021/acs.jpcb.8b07071
9. Comparative Perturbation Effects Exerted by the Influenza A M2 WT Protein Inhibitors Amantadine and the Spiro[pyrrolidine-2,2′-adamantane] Variant AK13 to Membrane Bilayers Studied Using Biophysical Experiments and Molecular Dynamics Simulations, A. Konstantinidi, N. Naziris, M. Chountoulesi, S. Kiriakidi, B. Sartori, D. Kolokouris, H. Amentisch, G. Mali , D. Ntountaniotis, C. Demetzos, T. Mavromoustakos, A. Kolocouris, The Journal of Physical Chemistry B, vol. 122, pp. 9877-9895, 2018, https://doi.org/10.1021/acs.jpcb.8b07071
10. Governing effects in the mechanism of the gold-catalyzed cycloisomerization of allenic hydroxylamine derivatives, S. Kiriakidi, O.N. Faza, A. Kolocouris, C.S. López Organic Biomolecular Chemistry, vol. 15, pp. 5920-5926, 2017, https://doi.org/10.1039/C7OB01275F
